IRI strategic options
This article was originally published in The Tan Sheet
Executive Summary
Chicago-based market researcher has retained William Blair & Co. investment banking firm "to assist the company in its exploration of strategic options," IRI says. Firm's strategic alternatives could include "sale of all or parts of the company, joint ventures, restructuring and capital infusions in order to enhance stockholder value and to better serve our customers," Feb. 26 release states. IRI has been reeling since P&G announced plans to sever its relationship with the share-data provider in July. Chap-Cap Partners investment group, a 5.5% IRI shareholder, sent recent letter demanding IRI Chairman, President and CEO Joseph Durrett step down or sell the firm (1"The Tan Sheet" Feb. 17, 2002 , In Brief)...You may also be interested in...
IRI on sales block?
Information Resources, Inc. shareholder Chap-Cap Partners pressures Chairman, CEO & President Joseph Durrett in Feb. 13 letter to "sell the company to the highest bidder" before "IRI's shareholders take it upon themselves to find another CEO and board of directors who will do so in your stead." El Segundo, Calif.-based investment group has collected a 5.6% stake in the market research firm since Jan. 8, shortly after Procter & Gamble announced plans to terminate its contract with IRI (1"The Tan Sheet" Dec. 16, 2002, In Brief). IRI reported flat worldwide revenues of $554.8 mil. in 2002 and a $13 mil. net loss, which followed a $3.9 mil. deficit the prior year...
Prenatal Vitamin D Benefit In Preventing Childhood Asthma Fades By Age 6
University of Rochester researchers say a benefit of daily prenatal vitamin D in preventing asthma in children up to 3 found in their 2016 study doesn't extend until age 6. They encourage more research, including analyzing whether supplementation should continue in young children.
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: